GlassScriptPhysician profile
Supriya Gupta
NPI 1124540604
$26,938.10
in general payments reported to CMS, 2019-2025
24 companies · $25K in 2025
The $25K reported for 2025 was more than what 87% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $522 · 2022: $991 · 2023: $478 · 2024: $14.57 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Honoraria: $11K · Travel and Lodging: $2,075 · Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,937.50 |
| Honoraria | $10,500.00 |
| Travel and Lodging | $2,074.80 |
| Food and Beverage | $912.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $12,259.29 | 2022-2025 | Opdivo, Opdualag |
| Adc Therapeutics America, INC. | $11,684.14 | 2023-2025 | |
| Celgene Corporation | $1,442.86 | 2022-2025 | Pomalyst |
| Astrazeneca Pharmaceuticals LP | $309.83 | 2021-2023 | Calquence |
| Eisai INC. | $186.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $150.57 | 2021-2023 | Lynparza, Keytruda |
| Seagen INC. | $137.63 | 2021-2022 | |
| Kite Pharma, INC. | $117.48 | 2022 | |
| Incyte Corporation | $99.99 | 2022 | |
| Amgen INC. | $99.95 | 2021 | |
| Daiichi Sankyo INC. | $98.93 | 2022-2023 | Injectafer, Enhertu |
| Global Blood Therapeutics, INC. | $66.72 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $53.28 | 2021 | |
| Novartis Pharmaceuticals Corporation | $39.90 | 2023 | |
| Beigene USA, INC. | $37.84 | 2023 | Brukinsa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $22.76 | 2023 | Epkinly |
| Stemline Therapeutics INC. | $20.22 | 2023 | Orserdu |
| Glaxosmithkline, LLC. | $18.36 | 2023 | Jemperli, Zejula |
| Sobi, INC | $16.75 | 2022 | |
| Astellas Pharma US INC | $16.06 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.80 | 2022 | |
| Janssen Biotech, INC. | $14.57 | 2024 | Tecvayli, Talvey |
| Genentech USA, INC. | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.